首页 > 最新文献

CHEST pulmonary最新文献

英文 中文
Cardiopulmonary Exercise Testing in Transgender and Gender-Diverse Patients 变性和性别差异患者的心肺运动测试:性别对预测有氧运动能力的影响
Pub Date : 2024-02-10 DOI: 10.1016/j.chpulm.2024.100040
Gustavo A. Cortes-Puentes MD , Thomas G. Allison PhD, MPH , Caroline J. Davidge-Pitts MBBCh , Cesar A. Gonzalez PhD, LP , Amanda R. Bonikowske PhD , Kaiser G. Lim MD , Cassie C. Kennedy MD

Background

Sex assigned at birth is currently used to calculate predicted normative values for oxygen consumption during cardiopulmonary exercise testing (CPET) in transgender and gender-diverse (TGD) patients. It is unclear if this is physiologically valid once gender-affirming hormonal therapy (GAHT) has been instituted.

Research Question

What are the changes in functional aerobic capacity (FAC) and % predicted peak oxygen consumption (V˙o2peak) when gender is used, instead of sex assigned at birth (SAB), to estimated normative predicted values among TGD patients aged > 14 years who are receiving GAHT?

Study Design and Methods

We retrospectively analyzed 16 referred TGD patients (eight transgender men and eight transgender women) receiving GAHT at the time of the test. Data collected and analyzed included the following: clinical indication for CPET, biometrics (age, height, and weight), CPET parameters (treadmill, Mayo Clinic protocol, without chest binder), chest imaging, echocardiographic results, and hemoglobin levels.

Results

In transgender women, the use of gender congruent normative predictive values, instead of SAB, significantly increased FAC (mean ± SE for SAB and gender, respectively, 69.70% ± 4.35% vs 87.82% ± 5.15%; P ≤ .0001) and % predicted Vo2peak (mean ± SE for SAB and gender, respectively, 66.53% ± 4.17% vs 89.69% ± 5.60%; P ≤ .0001). In transgender men, the use of gender congruent normative predictive values showed that both FAC and % predicted Vo2peak significantly decreased (approximately 20% and 25%, respectively). Deconditioning was the most frequent CPET finding among transgender men.

Interpretation

Among TGD individuals receiving GAHT, the use of gender to calculate normative values affects % predicted peak exercise oxygen consumption and FAC significantly. Body composition changes after GAHT require regular monitoring of muscle strength, lean body mass, and aerobic capacity. Cardiopulmonary symptoms among TGD patients should be assessed with these variables in mind, especially in the presence of chronic cardiac and pulmonary diseases.

背景目前,变性和性别多元化(TGD)患者在进行心肺运动测试(CPET)时,出生时的性别分配被用于计算耗氧量的预测标准值。研究问题当使用性别而不是出生时性别分配(SAB)来估算接受 GAHT 治疗的 14 岁 TGD 患者的正常预测值时,他们的有氧功能容量(FAC)和预测峰值耗氧量百分比(V˙o2peak)会发生哪些变化?研究设计与方法我们回顾性分析了 16 名转诊的 TGD 患者(8 名变性男性和 8 名变性女性)在接受 GAHT 测试时的情况。收集和分析的数据包括:CPET 的临床指征、生物统计学指标(年龄、身高和体重)、CPET 参数(跑步机、梅奥诊所方案,无胸部束缚器)、胸部成像、超声心动图结果和血红蛋白水平。结果在变性女性中,使用与性别一致的常模预测值而不是 SAB 可显著增加 FAC(SAB 和性别的平均值±SE 分别为 69.70% ± 4.35% vs 87.82% ± 5.15%;P ≤ .0001)和预测 Vo2peak%(SAB 和性别的平均值±SE 分别为 66.53% ± 4.17% vs 89.69% ± 5.60%;P ≤ .0001)。在变性男性中,使用性别一致的常模预测值显示,FAC 和预测 Vo2peak 百分比均显著下降(分别约为 20% 和 25%)。在接受 GAHT 治疗的 TGD 患者中,使用性别来计算标准值对预测峰值运动耗氧量和 FAC 的影响很大。接受 GAHT 治疗后身体成分发生变化,需要定期监测肌肉力量、瘦体重和有氧能力。在评估 TGD 患者的心肺症状时应考虑到这些变量,尤其是在患有慢性心肺疾病的情况下。
{"title":"Cardiopulmonary Exercise Testing in Transgender and Gender-Diverse Patients","authors":"Gustavo A. Cortes-Puentes MD ,&nbsp;Thomas G. Allison PhD, MPH ,&nbsp;Caroline J. Davidge-Pitts MBBCh ,&nbsp;Cesar A. Gonzalez PhD, LP ,&nbsp;Amanda R. Bonikowske PhD ,&nbsp;Kaiser G. Lim MD ,&nbsp;Cassie C. Kennedy MD","doi":"10.1016/j.chpulm.2024.100040","DOIUrl":"10.1016/j.chpulm.2024.100040","url":null,"abstract":"<div><h3>Background</h3><p>Sex assigned at birth is currently used to calculate predicted normative values for oxygen consumption during cardiopulmonary exercise testing (CPET) in transgender and gender-diverse (TGD) patients. It is unclear if this is physiologically valid once gender-affirming hormonal therapy (GAHT) has been instituted.</p></div><div><h3>Research Question</h3><p>What are the changes in functional aerobic capacity (FAC) and % predicted peak oxygen consumption (<span><math><mrow><mover><mi>V</mi><mo>˙</mo></mover></mrow></math></span><span>o</span><sub>2</sub>peak) when gender is used, instead of sex assigned at birth (SAB), to estimated normative predicted values among TGD patients aged &gt; 14 years who are receiving GAHT?</p></div><div><h3>Study Design and Methods</h3><p>We retrospectively analyzed 16 referred TGD patients (eight transgender men and eight transgender women) receiving GAHT at the time of the test. Data collected and analyzed included the following: clinical indication for CPET, biometrics (age, height, and weight), CPET parameters (treadmill, Mayo Clinic protocol, without chest binder), chest imaging, echocardiographic results, and hemoglobin levels.</p></div><div><h3>Results</h3><p>In transgender women, the use of gender congruent normative predictive values, instead of SAB, significantly increased FAC (mean ± SE for SAB and gender, respectively, 69.70% ± 4.35% vs 87.82% ± 5.15%; <em>P</em> ≤ .0001) and % predicted V<span>o</span><sub>2</sub>peak (mean ± SE for SAB and gender, respectively, 66.53% ± 4.17% vs 89.69% ± 5.60%; <em>P</em> ≤ .0001). In transgender men, the use of gender congruent normative predictive values showed that both FAC and % predicted V<span>o</span><sub>2</sub>peak significantly decreased (approximately 20% and 25%, respectively). Deconditioning was the most frequent CPET finding among transgender men.</p></div><div><h3>Interpretation</h3><p>Among TGD individuals receiving GAHT, the use of gender to calculate normative values affects % predicted peak exercise oxygen consumption and FAC significantly. Body composition changes after GAHT require regular monitoring of muscle strength, lean body mass, and aerobic capacity. Cardiopulmonary symptoms among TGD patients should be assessed with these variables in mind, especially in the presence of chronic cardiac and pulmonary diseases.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 2","pages":"Article 100040"},"PeriodicalIF":0.0,"publicationDate":"2024-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000060/pdfft?md5=47cc87f3f1c6c9e6732b881e3f2f869e&pid=1-s2.0-S2949789224000060-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139813663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiopulmonary Exercise Testing in Patients With Long COVID 长 COVID 患者的心肺运动测试:评估功能能力和运动限制
Pub Date : 2024-01-24 DOI: 10.1016/j.chpulm.2024.100036
Lotte Sørensen PhD , Camilla Lundgren Pedersen PT , Mads Jønsson Andersen MD, PhD , Johannes Martin Schmid MD, PhD , Lisa Gregersen Oestergaard PhD , Berit Schiøttz-Christensen MD , Søren Sperling MD

Background

After COVID-19, some patients present with ongoing symptoms (eg, breathlessness, exercise limitations), even after mild acute infection.

Research Question

What is the exercise capacity of patients diagnosed with long COVID and does it change from baseline to 1-year follow-up?

Study Design and Methods

This retrospective case series included patients with persistent symptoms after a confirmed diagnosis of COVID-19. Exercise capacity was examined by cardiopulmonary exercise testing (CPET), and parameters related to performance, ventilation, circulation, and gas exchange were compared with predicted values. A subgroup of patients was retested 1 year after baseline, and self-reported physical fitness was assessed at follow-up.

Results

In total, 169 patients completed baseline CPET and 41 patients completed 1-year follow-up. Mean maximum workload was 172 W (95% CI, 161-182), with 19% not achieving at least 84% predicted workload. Mean peak oxygen uptake was 24.4 mL/kg/min (95% CI, 23.1-25.7), and 36% had a value below % predicted. Oxygen uptake/workload slope below the normal threshold of 8.4 mL/min/W was observed in 54% of patients. The 1-year follow-up results showed no statistically significant changes in any of the CPET parameters, which correspond to lack of improvement in self-reported physical fitness.

Interpretation

Patients with long COVID demonstrated lowered peak oxygen uptake, oxygen uptake/workload slope, and/or ventilatory equivalent for carbon dioxide, but different parameters were lowered in different patients, illustrating a heterogeneous study population. No improvements in any parameters were found at 1-year follow-up.

背景COVID-19后,一些患者会出现持续症状(如呼吸困难、运动受限),即使是在轻度急性感染后也是如此。研究问题确诊为长COVID的患者的运动能力如何,从基线到1年随访期间运动能力是否会发生变化?通过心肺运动测试(CPET)检查患者的运动能力,并将与运动能力、通气、循环和气体交换相关的参数与预测值进行比较。结果共有 169 名患者完成了基线 CPET,41 名患者完成了为期 1 年的随访。平均最大工作量为 172 W(95% CI,161-182),19% 的患者未达到至少 84% 的预测工作量。平均峰值摄氧量为 24.4 mL/kg/min(95% CI,23.1-25.7),36% 的摄氧量低于预测值。54%的患者的摄氧量/工作量斜率低于正常阈值 8.4 毫升/分钟/瓦。长 COVID 患者的峰值摄氧量、摄氧量/工作负荷斜率和/或二氧化碳通气当量均有所降低,但不同患者的参数降低程度不同,这说明研究对象具有异质性。在为期一年的随访中,没有发现任何参数有所改善。
{"title":"Cardiopulmonary Exercise Testing in Patients With Long COVID","authors":"Lotte Sørensen PhD ,&nbsp;Camilla Lundgren Pedersen PT ,&nbsp;Mads Jønsson Andersen MD, PhD ,&nbsp;Johannes Martin Schmid MD, PhD ,&nbsp;Lisa Gregersen Oestergaard PhD ,&nbsp;Berit Schiøttz-Christensen MD ,&nbsp;Søren Sperling MD","doi":"10.1016/j.chpulm.2024.100036","DOIUrl":"10.1016/j.chpulm.2024.100036","url":null,"abstract":"<div><h3>Background</h3><p>After COVID-19, some patients present with ongoing symptoms (eg, breathlessness, exercise limitations), even after mild acute infection.</p></div><div><h3>Research Question</h3><p>What is the exercise capacity of patients diagnosed with long COVID and does it change from baseline to 1-year follow-up?</p></div><div><h3>Study Design and Methods</h3><p>This retrospective case series included patients with persistent symptoms after a confirmed diagnosis of COVID-19. Exercise capacity was examined by cardiopulmonary exercise testing (CPET), and parameters related to performance, ventilation, circulation, and gas exchange were compared with predicted values. A subgroup of patients was retested 1 year after baseline, and self-reported physical fitness was assessed at follow-up.</p></div><div><h3>Results</h3><p>In total, 169 patients completed baseline CPET and 41 patients completed 1-year follow-up. Mean maximum workload was 172 W (95% CI, 161-182), with 19% not achieving at least 84% predicted workload. Mean peak oxygen uptake was 24.4 mL/kg/min (95% CI, 23.1-25.7), and 36% had a value below % predicted. Oxygen uptake/workload slope below the normal threshold of 8.4 mL/min/W was observed in 54% of patients. The 1-year follow-up results showed no statistically significant changes in any of the CPET parameters, which correspond to lack of improvement in self-reported physical fitness.</p></div><div><h3>Interpretation</h3><p>Patients with long COVID demonstrated lowered peak oxygen uptake, oxygen uptake/workload slope, and/or ventilatory equivalent for carbon dioxide, but different parameters were lowered in different patients, illustrating a heterogeneous study population. No improvements in any parameters were found at 1-year follow-up.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 2","pages":"Article 100036"},"PeriodicalIF":0.0,"publicationDate":"2024-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789224000023/pdfft?md5=9e470b0313c45124451b2141b1a32449&pid=1-s2.0-S2949789224000023-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139635900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Employment of the Envisia Genomic Classifier in Conjunction With Cryobiopsy in Patients With Undiagnosed Interstitial Lung Disease 将 Envisia 基因组分类器与冷冻活组织切片检查相结合,用于未确诊的间质性肺病患者
Pub Date : 2023-12-27 DOI: 10.1016/j.chpulm.2023.100034
Fayez Kheir MD , Ramsy Abdelghani MD , Diana Espinoza MD , Regina Villalobos MD , David Becnel MD , Rachel Herr MD , Alejandro Aragaki MD , J.P. Uribe Becerra MD , Justin M. Oldham MD , Joseph Lasky MD

Background

The Envisia Genomic Classifier (EGC) is a clinically validated molecular diagnostic test identifying usual interstitial pneumonia (UIP), increasing the diagnostic confidence for idiopathic pulmonary fibrosis in patients with interstitial lung disease (ILD).

Research Question

What is the association of the EGC and lung cryobiopsy on clinical management decisions in patients with fibrotic ILD?

Study Design and Methods

Retrospective analysis of patients at multimedical centers. We assessed the change in management strategy after EGC and cryobiopsy. We evaluated the association between genomic UIP classification and disease progression using the American Thoracic Society definition of progressive pulmonary fibrosis (method 1), or combined end point of death from any cause, lung transplant, or ≥ 10% relative decline in FVC (method 2).

Results

In patients that were EGC positive for UIP (gcUIP+), 78.6% were diagnosed with idiopathic pulmonary fibrosis. Cryobiopsy and EGC test results changed management strategy for 59.5% of patients in the cohort that were gcUIP+, and 21.4% of patients that had indeterminate cryobiopsy interpretations were gcUIP+, leading to a change in treatment strategy of an additional 16.7%. There was a decrease in follow-up without treatment from 64.3% to 11.9% (P < .001). Utilization of immunosuppressive drugs decreased from 23.8% to 9.5% (P = .06), and there was an increase in treatment with antifibrotics drugs from 11.9% to 71.4% (P < .001). A Kaplan-Meier curve of disease progression did not reach statistical significance on multivariable analysis (method 1: hazard ratio, 1.4; 95% CI, 0.4-4.2; P = .55; method 2: hazard ratio, 1.3; 95% CI, 0.8-2.1; P = .29). In analysis of EGC positivity for UIP, patients who were not prescribed antifibrotics showed disease progression compared with patients who were EGC negative for UIP (hazard ratio, 1.8; 95% CI, 0.99-3.4; P = .053)

Interpretation

This study suggests that combined EGC and cryobiopsy are associated with change in therapeutic strategy in patients with undiagnosed ILD. The EGC might serve as a predictor for disease progression in patients not treated with antifibrotics.

研究背景Envisia基因组分类器(EGC)是一种经过临床验证的分子诊断测试,可识别寻常间质性肺炎(UIP),提高间质性肺病(ILD)患者特发性肺纤维化的诊断可信度。研究问题EGC和肺冷冻活检与纤维化ILD患者的临床管理决策有何关联?我们评估了 EGC 和冷冻活检后管理策略的变化。我们使用美国胸科学会关于进展性肺纤维化的定义(方法 1)或任何原因死亡、肺移植或 FVC 相对下降≥10% 的合并终点(方法 2)评估了基因组 UIP 分类与疾病进展之间的关联。冷冻活检和 EGC 检测结果改变了队列中 59.5% 的 gcUIP+ 患者的治疗策略,在冷冻活检结果不确定的患者中,有 21.4% 为 gcUIP+,导致另外 16.7% 的患者改变了治疗策略。未接受治疗的随访率从 64.3% 降至 11.9%(P < .001)。免疫抑制剂的使用率从23.8%降至9.5%(P = .06),抗纤维化药物的使用率从11.9%增至71.4%(P < .001)。疾病进展的 Kaplan-Meier 曲线在多变量分析中未达到统计学意义(方法 1:危险比,1.4;95% CI,0.4-4.2;P = .55;方法 2:危险比,1.3;95% CI,0.8-2.1;P = .29)。在分析 EGC 阳性 UIP 时,与 EGC 阴性 UIP 患者相比,未使用抗纤维化药物的患者病情出现进展(危险比为 1.8;95% CI 为 0.99-3.4;P = .053)。在未接受抗纤维化药物治疗的患者中,EGC可作为疾病进展的预测指标。
{"title":"Employment of the Envisia Genomic Classifier in Conjunction With Cryobiopsy in Patients With Undiagnosed Interstitial Lung Disease","authors":"Fayez Kheir MD ,&nbsp;Ramsy Abdelghani MD ,&nbsp;Diana Espinoza MD ,&nbsp;Regina Villalobos MD ,&nbsp;David Becnel MD ,&nbsp;Rachel Herr MD ,&nbsp;Alejandro Aragaki MD ,&nbsp;J.P. Uribe Becerra MD ,&nbsp;Justin M. Oldham MD ,&nbsp;Joseph Lasky MD","doi":"10.1016/j.chpulm.2023.100034","DOIUrl":"https://doi.org/10.1016/j.chpulm.2023.100034","url":null,"abstract":"<div><h3>Background</h3><p>The Envisia Genomic Classifier (EGC) is a clinically validated molecular diagnostic test identifying usual interstitial pneumonia (UIP), increasing the diagnostic confidence for idiopathic pulmonary fibrosis in patients with interstitial lung disease (ILD).</p></div><div><h3>Research Question</h3><p>What is the association of the EGC and lung cryobiopsy on clinical management decisions in patients with fibrotic ILD?</p></div><div><h3>Study Design and Methods</h3><p>Retrospective analysis of patients at multimedical centers. We assessed the change in management strategy after EGC and cryobiopsy. We evaluated the association between genomic UIP classification and disease progression using the American Thoracic Society definition of progressive pulmonary fibrosis (method 1), or combined end point of death from any cause, lung transplant, or ≥ 10% relative decline in FVC (method 2).</p></div><div><h3>Results</h3><p>In patients that were EGC positive for UIP (gcUIP+), 78.6% were diagnosed with idiopathic pulmonary fibrosis. Cryobiopsy and EGC test results changed management strategy for 59.5% of patients in the cohort that were gcUIP+, and 21.4% of patients that had indeterminate cryobiopsy interpretations were gcUIP+, leading to a change in treatment strategy of an additional 16.7%. There was a decrease in follow-up without treatment from 64.3% to 11.9% (<em>P</em> &lt; .001). Utilization of immunosuppressive drugs decreased from 23.8% to 9.5% (<em>P</em> = .06), and there was an increase in treatment with antifibrotics drugs from 11.9% to 71.4% (<em>P</em> &lt; .001). A Kaplan-Meier curve of disease progression did not reach statistical significance on multivariable analysis (method 1: hazard ratio, 1.4; 95% CI, 0.4-4.2; <em>P</em> = .55; method 2: hazard ratio, 1.3; 95% CI, 0.8-2.1; <em>P</em> = .29). In analysis of EGC positivity for UIP, patients who were not prescribed antifibrotics showed disease progression compared with patients who were EGC negative for UIP (hazard ratio, 1.8; 95% CI, 0.99-3.4; <em>P</em> = .053)</p></div><div><h3>Interpretation</h3><p>This study suggests that combined EGC and cryobiopsy are associated with change in therapeutic strategy in patients with undiagnosed ILD. The EGC might serve as a predictor for disease progression in patients not treated with antifibrotics.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 2","pages":"Article 100034"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S294978922300034X/pdfft?md5=3a31e647a9df7ad6aaacd911645e1704&pid=1-s2.0-S294978922300034X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140551629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thymoma as a Potential Risk Factor for Nontuberculous Mycobacterial Pulmonary Disease 胸腺瘤是非结核分枝杆菌肺病的潜在危险因素:病例系列
Pub Date : 2023-12-09 DOI: 10.1016/j.chpulm.2023.100032
Marie Yan MD, MSc , Sarah K. Brode MD, MSc , Theodore K. Marras MD, MSc
{"title":"Thymoma as a Potential Risk Factor for Nontuberculous Mycobacterial Pulmonary Disease","authors":"Marie Yan MD, MSc ,&nbsp;Sarah K. Brode MD, MSc ,&nbsp;Theodore K. Marras MD, MSc","doi":"10.1016/j.chpulm.2023.100032","DOIUrl":"10.1016/j.chpulm.2023.100032","url":null,"abstract":"","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"2 2","pages":"Article 100032"},"PeriodicalIF":0.0,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000326/pdfft?md5=ac77814e7af987814b077d89c5ad9c25&pid=1-s2.0-S2949789223000326-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138617894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing Pulmonary Complications in Adults With Cerebral Palsy 处理脑瘫成人的肺部并发症
Pub Date : 2023-12-01 DOI: 10.1016/j.chpulm.2023.100025
Brinda Desai MD , Daniel J. Lesser MD , Bernie Y. Sunwoo MBBS

Cerebral palsy is the most common motor disability in childhood with increasing survival rates into adulthood. Pulmonary complications are a leading cause of morbidity and mortality in this population. However, adult pulmonologists are rarely trained on how to receive these patients into their practice, including how best to identify and manage pulmonary complications. Quality studies on pulmonary complications in cerebral palsy, both in the adult and pediatric population, are lacking, but we review the available literature to provide an approach for the adult pulmonologist in identifying risk factors for pulmonary complications including aspiration, impaired airway clearance, airways disease, neuromuscular scoliosis and restrictive chest wall disease, sleep-disordered breathing, and hypoventilation. We provide a framework to help manage these pulmonary complications and plan and organize successful multidisciplinary transition of pulmonary care from adolescence to adulthood, largely extrapolating from small pediatric studies, studies on neurodevelopmental disorders in general, international guidelines, and clinical experiences, until more quality studies on this topic are available.

脑性瘫痪是儿童时期最常见的运动性残疾,成年后的存活率越来越高。肺部并发症是这一人群发病和死亡的主要原因。然而,成人肺科医生很少接受过如何接诊这类患者的培训,包括如何最好地识别和处理肺部并发症。虽然缺乏对成人和儿童脑瘫患者肺部并发症的高质量研究,但我们回顾了现有文献,为成人肺科医生提供了一种识别肺部并发症风险因素的方法,包括吸入、气道通畅障碍、气道疾病、神经肌肉性脊柱侧弯和限制性胸壁疾病、睡眠呼吸障碍和通气不足。我们提供了一个框架,以帮助管理这些肺部并发症,并计划和组织从青少年到成年的多学科肺部护理的成功过渡,这主要是从小型儿科研究、一般神经发育障碍研究、国际指南和临床经验中推断出来的,直到有更多关于此主题的高质量研究。
{"title":"Managing Pulmonary Complications in Adults With Cerebral Palsy","authors":"Brinda Desai MD ,&nbsp;Daniel J. Lesser MD ,&nbsp;Bernie Y. Sunwoo MBBS","doi":"10.1016/j.chpulm.2023.100025","DOIUrl":"10.1016/j.chpulm.2023.100025","url":null,"abstract":"<div><p>Cerebral palsy is the most common motor disability in childhood with increasing survival rates into adulthood. Pulmonary complications are a leading cause of morbidity and mortality in this population. However, adult pulmonologists are rarely trained on how to receive these patients into their practice, including how best to identify and manage pulmonary complications. Quality studies on pulmonary complications in cerebral palsy, both in the adult and pediatric population, are lacking, but we review the available literature to provide an approach for the adult pulmonologist in identifying risk factors for pulmonary complications including aspiration, impaired airway clearance, airways disease, neuromuscular scoliosis and restrictive chest wall disease, sleep-disordered breathing, and hypoventilation. We provide a framework to help manage these pulmonary complications and plan and organize successful multidisciplinary transition of pulmonary care from adolescence to adulthood, largely extrapolating from small pediatric studies, studies on neurodevelopmental disorders in general, international guidelines, and clinical experiences, until more quality studies on this topic are available.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 3","pages":"Article 100025"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000259/pdfft?md5=1932c9aead8e0aee90fcf8ffdd5fbeb3&pid=1-s2.0-S2949789223000259-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135654719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Protocol for the Veterans Affairs Cooperative Studies Program Study Number 2005 退伍军人事务合作研究计划 2005 年研究号议定书
Pub Date : 2023-12-01 DOI: 10.1016/j.chpulm.2023.100024
Drew Moghanaki MD, MPH , Tomer Karas MD , Robert D. Timmerman MD , Robert B. Cameron MD , Timothy A. Ritter PhD , Hairong Shi PhD , Matthew K. Leiner MS , Hua Feng PhD , Vicki L. Skinner RN, MSN , Lisa Robin MA , Cheryl Odle MBA , Tom Sindowski BS , Amanda J. Snodgrass PharmD , Grant D. Huang MPH, PhD , Domenic J. Reda PhD , David H. Harpole MD , Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Study Team

Background

Standard-of-care treatment options for stage I non-small cell lung cancer (NSCLC) include surgery and stereotactic body radiation therapy (SBRT). Notwithstanding a lack of prospective evidence demonstrating superior long-term survival with either of these treatments, evidence-based guidelines currently recommend only surgery for patients with operable disease and to limit SBRT for patients with inoperable disease.

Research Question

Do surgery or SBRT lead to superior survival rates for operable stage I NSCLC?

Study Design and Methods

A phase 3 randomized clinical trial was designed to compare the overall survival (OS) rates after surgery or SBRT for stage I NSCLC. Eligible participants must have biopsy-confirmed NSCLC measuring ≤ 5 cm in maximum diameter located > 1 cm from the trachea, proximal bronchial tree, esophagus, and spinal cord. Participants must be staged with fluorodeoxyglucose PET scans with mandatory biopsies of all radiographic areas concerning for regional or distant metastatic disease. The planned accrual is 670 patients to detect a 10% absolute benefit in 5-year OS with surgery or SBRT. Secondary outcome measures include patient-reported quality of life, respiratory function, health state utilities, patterns of lung cancer relapse, and causes of mortality by independent adjudication.

Results

The study was initiated in April 2017 with a planned ramp-up phase at six Veterans Affairs medical centers. Adapted recruitment interventions contributed to overcoming historical barriers to randomizing eligible participants between surgery and SBRT, and the study was expanded to 16 sites in May 2019. As of July 5, 2023, 280 of 670 planned participants have been enrolled.

Interpretation

The final results are expected to clarify the role of SBRT in lieu of surgery for patients with operable stage I NSCLC and to facilitate more informed discussions about these treatment options.

Trial Registry

ClinicalTrials.gov; No.: NCT02984761; URL: www.clinicaltrials.gov

背景I期非小细胞肺癌(NSCLC)的常规治疗方案包括手术和立体定向体放射治疗(SBRT)。尽管缺乏前瞻性证据证明这两种治疗方法的长期生存率更高,但循证指南目前只建议对可手术的患者进行手术治疗,并限制对不可手术的患者进行SBRT治疗。研究问题对于可手术的I期NSCLC,手术或SBRT是否能带来更高的生存率? 研究设计与方法一项3期随机临床试验旨在比较I期NSCLC手术或SBRT治疗后的总生存率(OS)。符合条件的参与者必须是经活检证实的NSCLC,最大直径不超过5厘米,距离气管、近端支气管、食管和脊髓1厘米。参与者必须通过氟脱氧葡萄糖 PET 扫描进行分期,并对所有涉及区域或远处转移性疾病的放射区域进行强制性活检。计划招募 670 名患者,以检测手术或 SBRT 对患者 5 年生存率是否有 10% 的绝对益处。次要结局指标包括患者报告的生活质量、呼吸功能、健康状态效用、肺癌复发模式以及独立裁定的死亡原因。经过调整的招募干预措施有助于克服在手术和SBRT之间对符合条件的参与者进行随机分配的历史障碍,该研究于2019年5月扩展到16个地点。截至2023年7月5日,计划招募的670名参与者中已有280名被招募。解读最终结果有望明确SBRT在可手术的I期NSCLC患者中替代手术的作用,并促进关于这些治疗方案的讨论。
{"title":"Protocol for the Veterans Affairs Cooperative Studies Program Study Number 2005","authors":"Drew Moghanaki MD, MPH ,&nbsp;Tomer Karas MD ,&nbsp;Robert D. Timmerman MD ,&nbsp;Robert B. Cameron MD ,&nbsp;Timothy A. Ritter PhD ,&nbsp;Hairong Shi PhD ,&nbsp;Matthew K. Leiner MS ,&nbsp;Hua Feng PhD ,&nbsp;Vicki L. Skinner RN, MSN ,&nbsp;Lisa Robin MA ,&nbsp;Cheryl Odle MBA ,&nbsp;Tom Sindowski BS ,&nbsp;Amanda J. Snodgrass PharmD ,&nbsp;Grant D. Huang MPH, PhD ,&nbsp;Domenic J. Reda PhD ,&nbsp;David H. Harpole MD ,&nbsp;Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy Study Team","doi":"10.1016/j.chpulm.2023.100024","DOIUrl":"10.1016/j.chpulm.2023.100024","url":null,"abstract":"<div><h3>Background</h3><p>Standard-of-care treatment options for stage I non-small cell lung cancer (NSCLC) include surgery and stereotactic body radiation therapy (SBRT). Notwithstanding a lack of prospective evidence demonstrating superior long-term survival with either of these treatments, evidence-based guidelines currently recommend only surgery for patients with operable disease and to limit SBRT for patients with inoperable disease.</p></div><div><h3>Research Question</h3><p>Do surgery or SBRT lead to superior survival rates for operable stage I NSCLC?</p></div><div><h3>Study Design and Methods</h3><p>A phase 3 randomized clinical trial was designed to compare the overall survival (OS) rates after surgery or SBRT for stage I NSCLC. Eligible participants must have biopsy-confirmed NSCLC measuring ≤ 5 cm in maximum diameter located &gt; 1 cm from the trachea, proximal bronchial tree, esophagus, and spinal cord. Participants must be staged with fluorodeoxyglucose PET scans with mandatory biopsies of all radiographic areas concerning for regional or distant metastatic disease. The planned accrual is 670 patients to detect a 10% absolute benefit in 5-year OS with surgery or SBRT. Secondary outcome measures include patient-reported quality of life, respiratory function, health state utilities, patterns of lung cancer relapse, and causes of mortality by independent adjudication.</p></div><div><h3>Results</h3><p>The study was initiated in April 2017 with a planned ramp-up phase at six Veterans Affairs medical centers. Adapted recruitment interventions contributed to overcoming historical barriers to randomizing eligible participants between surgery and SBRT, and the study was expanded to 16 sites in May 2019. As of July 5, 2023, 280 of 670 planned participants have been enrolled.</p></div><div><h3>Interpretation</h3><p>The final results are expected to clarify the role of SBRT in lieu of surgery for patients with operable stage I NSCLC and to facilitate more informed discussions about these treatment options.</p></div><div><h3>Trial Registry</h3><p>ClinicalTrials.gov; No.: NCT02984761; URL: <span>www.clinicaltrials.gov</span><svg><path></path></svg></p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 3","pages":"Article 100024"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000247/pdfft?md5=c61f19856ae17cebb90a23eea4287320&pid=1-s2.0-S2949789223000247-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134936296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Multilevel Risk Factors for Sleep-Disordered Breathing-Related Symptom Burden in an Urban Pediatric Community-Based Sample 城市儿科社区样本中睡眠呼吸障碍相关症状负担的多层次风险因素
Pub Date : 2023-12-01 DOI: 10.1016/j.chpulm.2023.100019
Seyni Gueye-Ndiaye MD , Marissa Hauptman MD, MPH , Xinting Yu MD, PhD , Le Li MS , Michael Rueschman MPH , Cecilia Castro-Diehl DrPH , Tamar Sofer PhD , Judith Owens MD, MPH , Diane R. Gold MD, MPH , Gary Adamkiewicz PhD, MPH , Nervana Metwali PhD , Peter S. Thorne PhD , Wanda Phipatanakul MD , Susan Redline MD, MPH

Background

Pediatric sleep-disordered breathing (SDB) disproportionately affects children with low socioeconomic status (SES). The multilevel risk factors that drive these associations are not well understood.

Research Question

What are the associations between SDB risk factors, including individual health conditions (obesity, asthma, and allergies), household SES (maternal education), indoor exposures (environmental tobacco smoke [ETS] and pests), and neighborhood characteristics (neighborhood disadvantage), and pediatric SDB symptoms?

Study Design and Methods

Cross-sectional analyses were performed on 303 children (aged 6-12 years) enrolled in the Environmental Assessment of Sleep Youth study from 2018 to 2022. Exposures were determined by caregiver reports, assays of measured settled dust from the child’s bedroom, and neighborhood-level Census data (deriving the Childhood Opportunity Index to characterize neighborhood disadvantage). The primary outcome was the SDB-related symptom burden assessed by the OSA-18 questionnaire total score. Using linear regression models, we calculated associations between exposures and SDB-related symptom burden, adjusting for sociodemographic factors, then health conditions, indoor environment, and neighborhood factors.

Results

The sample included 303 children (39% Hispanic, Latino, Latina, or Spanish origin; 30% Black or African American; 22% White; and 11% other). Increasing OSA-18 total scores were associated with low household SES after adjustment for demographic factors, and with asthma, allergies, ETS, pests (mouse, cockroach, and rodents), and an indoor environmental index (sum of the presence of pests and ETS; 0-2) after adjusting for sociodemographic factors. Even after further adjusting for asthma, allergies, and neighborhood disadvantage, ETS and pest exposure were associated with OSA-18 (ETS: β = 12.80; 95% CI, 7.07-18.53, also adjusted for pest; pest exposure: β = 3.69; 95% CI, 0.44-6.94, also adjusted for ETS).

Interpretation

In addition to associations with ETS, a novel association was observed for indoor pest exposure and SDB symptom burden. Strategies to reduce household exposure to ETS and indoor allergens should be tested as approaches for reducing sleep health disparities.

背景小儿睡眠呼吸障碍(SDB)对社会经济地位(SES)较低的儿童的影响尤为严重。研究问题SDB风险因素(包括个人健康状况(肥胖、哮喘和过敏)、家庭SES(母亲教育程度)、室内暴露(环境烟草烟雾[ETS]和害虫)和邻里特征(邻里劣势))与小儿SDB症状之间存在哪些关联?研究设计与方法对2018年至2022年参加青少年睡眠环境评估研究的303名儿童(6-12岁)进行了横断面分析。通过护理人员的报告、对儿童卧室沉降尘埃的测定以及邻里一级的人口普查数据(得出儿童机会指数以描述邻里劣势)来确定暴露情况。主要结果是通过 OSA-18 问卷总分评估与 SDB 相关的症状负担。通过线性回归模型,我们计算了暴露与 SDB 相关症状负担之间的关系,并对社会人口因素、健康状况、室内环境和邻里因素进行了调整。结果样本包括 303 名儿童(39% 为西班牙裔、拉丁裔、拉美裔或西班牙血统;30% 为黑人或非裔美国人;22% 为白人;11% 为其他血统)。在对人口因素进行调整后,OSA-18 总分的增加与低家庭社会经济地位有关;在对社会人口因素进行调整后,OSA-18 总分的增加与哮喘、过敏、有害气体、害虫(老鼠、蟑螂和啮齿类动物)以及室内环境指数(害虫和有害气体存在的总和;0-2)有关。即使在进一步调整了哮喘、过敏和邻里劣势等因素后,排放有毒有害物质和虫害暴露仍与 OSA-18 相关(排放有毒有害物质:β = 12.80;95% CI,7.07-18.53,也根据虫害进行了调整;虫害暴露:β = 3.69;95% CI,0.44-6.94,也根据排放有毒有害物质进行了调整)。减少家庭接触有害环境气体和室内过敏原的策略应作为减少睡眠健康差异的方法进行测试。
{"title":"Multilevel Risk Factors for Sleep-Disordered Breathing-Related Symptom Burden in an Urban Pediatric Community-Based Sample","authors":"Seyni Gueye-Ndiaye MD ,&nbsp;Marissa Hauptman MD, MPH ,&nbsp;Xinting Yu MD, PhD ,&nbsp;Le Li MS ,&nbsp;Michael Rueschman MPH ,&nbsp;Cecilia Castro-Diehl DrPH ,&nbsp;Tamar Sofer PhD ,&nbsp;Judith Owens MD, MPH ,&nbsp;Diane R. Gold MD, MPH ,&nbsp;Gary Adamkiewicz PhD, MPH ,&nbsp;Nervana Metwali PhD ,&nbsp;Peter S. Thorne PhD ,&nbsp;Wanda Phipatanakul MD ,&nbsp;Susan Redline MD, MPH","doi":"10.1016/j.chpulm.2023.100019","DOIUrl":"10.1016/j.chpulm.2023.100019","url":null,"abstract":"<div><h3>Background</h3><p>Pediatric sleep-disordered breathing (SDB) disproportionately affects children with low socioeconomic status (SES). The multilevel risk factors that drive these associations are not well understood.</p></div><div><h3>Research Question</h3><p>What are the associations between SDB risk factors, including individual health conditions (obesity, asthma, and allergies), household SES (maternal education), indoor exposures (environmental tobacco smoke [ETS] and pests), and neighborhood characteristics (neighborhood disadvantage), and pediatric SDB symptoms?</p></div><div><h3>Study Design and Methods</h3><p>Cross-sectional analyses were performed on 303 children (aged 6-12 years) enrolled in the Environmental Assessment of Sleep Youth study from 2018 to 2022. Exposures were determined by caregiver reports, assays of measured settled dust from the child’s bedroom, and neighborhood-level Census data (deriving the Childhood Opportunity Index to characterize neighborhood disadvantage). The primary outcome was the SDB-related symptom burden assessed by the OSA-18 questionnaire total score. Using linear regression models, we calculated associations between exposures and SDB-related symptom burden, adjusting for sociodemographic factors, then health conditions, indoor environment, and neighborhood factors.</p></div><div><h3>Results</h3><p>The sample included 303 children (39% Hispanic, Latino, Latina, or Spanish origin; 30% Black or African American; 22% White; and 11% other). Increasing OSA-18 total scores were associated with low household SES after adjustment for demographic factors, and with asthma, allergies, ETS, pests (mouse, cockroach, and rodents), and an indoor environmental index (sum of the presence of pests and ETS; 0-2) after adjusting for sociodemographic factors. Even after further adjusting for asthma, allergies, and neighborhood disadvantage, ETS and pest exposure were associated with OSA-18 (ETS: β = 12.80; 95% CI, 7.07-18.53, also adjusted for pest; pest exposure: β = 3.69; 95% CI, 0.44-6.94, also adjusted for ETS).</p></div><div><h3>Interpretation</h3><p>In addition to associations with ETS, a novel association was observed for indoor pest exposure and SDB symptom burden. Strategies to reduce household exposure to ETS and indoor allergens should be tested as approaches for reducing sleep health disparities.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 3","pages":"Article 100019"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000193/pdfft?md5=91aa07089927f75d999f540745cff438&pid=1-s2.0-S2949789223000193-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135249489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short of Breath and Teary-Eyed 气喘吁吁,泪眼婆娑
Pub Date : 2023-12-01 DOI: 10.1016/j.chpulm.2023.100015
Bilal Al Kalaji MD, Saad Khan MD, Abdelraouf Salah MD, Ahmad Harb MD, Grace Ying DO, Alok Patel MD

Case Presentation

A 78-year-old man is admitted to the ICU for acute respiratory distress requiring endotracheal intubation. The patient was in his usual state of health and had seen his primary care physician earlier that day for a routine visit and influenza immunization. Later in the evening, the patient developed acutely worsening shortness of breath. He had no fever or chills, worsening cough, purulent sputum, wheezing, stridor, chest pain, palpitation, or known sick contacts. Family members noted that his face looked puffy, but he did not have lip or tongue swelling, difficulty swallowing, odynophagia, or a new rash. On ambulance arrival, the patient was noted to have significant respiratory distress. He was subsequently intubated at the scene and transferred to the hospital for further evaluation and management. The patient was known to have paroxysmal atrial fibrillation and COPD requiring 2 to 4 L of oxygen via nasal cannula at baseline. Social history was notable for prior use of tobacco. Family history was negative for allergies, pulmonary disease, and malignancy. The patient was last hospitalized for COPD exacerbation > 1 year prior to this admission. Otherwise, he remained adequately adherent to his COPD treatment.

病例介绍一名78岁男性因急性呼吸窘迫需要气管插管而住进ICU。患者健康状况正常,当天早些时候曾见过初级保健医生进行常规检查和流感免疫接种。晚些时候,患者出现急剧恶化的呼吸短促。他没有发热或发冷、咳嗽加重、脓性痰、喘息、喘鸣、胸痛、心悸或已知的患病接触者。家人注意到他的脸看起来浮肿,但他没有嘴唇或舌头肿胀、吞咽困难、吞咽困难或新的皮疹。救护车到达时,注意到患者有明显的呼吸窘迫。随后,他在现场插管,并被转移到医院进行进一步的评估和处理。已知患者患有阵发性心房颤动和慢性阻塞性肺病,基线时需要2至4l的鼻插管供氧。社会历史上有明显的烟草使用史。家族史没有过敏、肺部疾病和恶性肿瘤。患者最后一次住院是因为COPD加重>入学前一年。除此之外,他仍然充分坚持他的COPD治疗。
{"title":"Short of Breath and Teary-Eyed","authors":"Bilal Al Kalaji MD,&nbsp;Saad Khan MD,&nbsp;Abdelraouf Salah MD,&nbsp;Ahmad Harb MD,&nbsp;Grace Ying DO,&nbsp;Alok Patel MD","doi":"10.1016/j.chpulm.2023.100015","DOIUrl":"10.1016/j.chpulm.2023.100015","url":null,"abstract":"<div><h3>Case Presentation</h3><p>A 78-year-old man is admitted to the ICU for acute respiratory distress requiring endotracheal intubation. The patient was in his usual state of health and had seen his primary care physician earlier that day for a routine visit and influenza immunization. Later in the evening, the patient developed acutely worsening shortness of breath. He had no fever or chills, worsening cough, purulent sputum, wheezing, stridor, chest pain, palpitation, or known sick contacts. Family members noted that his face looked puffy, but he did not have lip or tongue swelling, difficulty swallowing, odynophagia, or a new rash. On ambulance arrival, the patient was noted to have significant respiratory distress. He was subsequently intubated at the scene and transferred to the hospital for further evaluation and management. The patient was known to have paroxysmal atrial fibrillation and COPD requiring 2 to 4 L of oxygen via nasal cannula at baseline. Social history was notable for prior use of tobacco. Family history was negative for allergies, pulmonary disease, and malignancy. The patient was last hospitalized for COPD exacerbation &gt; 1 year prior to this admission. Otherwise, he remained adequately adherent to his COPD treatment.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 3","pages":"Article 100015"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000156/pdfft?md5=57d56e2d786eeccc3e16c1de148eea11&pid=1-s2.0-S2949789223000156-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135255414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies 炎症性肠病的肺部表现和治疗策略
Pub Date : 2023-12-01 DOI: 10.1016/j.chpulm.2023.100018
Subha Ghosh MD, MBA , Himanshu Deshwal MD , Rebecca Haraf MD , Shine Raju MD , Mnahi Bin Saeedan MBBS, MPH , Pralay Sarkar MD, FCCP , Thomas Gildea MD , Carol F. Farver MD , Atul C. Mehta MD, FCCP

Topic Importance

Ulcerative colitis and Crohn’s disease are multisystem illnesses that primarily affect the gut, but present with various extraintestinal manifestations. The pathogenesis behind these clinical features is poorly understood, and pulmonary manifestations of inflammatory bowel disease (IBD) are no exception. Research has suggested an intricate interplay between the mucosal immune system and the microbiotic environment between the gut and the lung, often termed the gut-lung axis. This dysregulated communication is demonstrated in a wide range of pulmonary complications involving the large and small airways, lung parenchyma, serosal tissues, and pulmonary vasculature; fistulous connection between the gastrointestinal tract and thoracic cavity; and drug toxicities. Most of these diseases have been well documented in case reports to respond to corticosteroid treatment regimens. However, a notable lack of treatment recommendations guiding the dosage and duration of steroid use and managing the disease refractory to therapy are available. In addition, the progressive and debilitating disease often remains a therapeutic challenge.

Review Findings

This review sheds light on the different strategies documented to treat the spectrum of pulmonary complications of IBD, including novel therapeutic approaches using immunomodulatory therapy, and summarizes their clinical and radiologic features with pathologic correlation.

Summary

Although their existence is well documented, further research is needed to develop evidence-based guidelines for diagnosing, managing, and preventing pulmonary complications of IBD.

主题重要性溃疡性结肠炎和克罗恩病是一种多系统疾病,主要影响肠道,但会出现各种肠道外表现。人们对这些临床特征背后的发病机制知之甚少,炎症性肠病(IBD)的肺部表现也不例外。研究表明,粘膜免疫系统与肠道和肺部之间的微生物环境之间存在着错综复杂的相互作用,这通常被称为肠肺轴。这种失调的交流体现在涉及大、小气道、肺实质、浆膜组织和肺血管的各种肺部并发症;胃肠道和胸腔之间的瘘管连接;以及药物毒性。在病例报告中,这些疾病大多对皮质类固醇治疗方案反应良好。然而,目前明显缺乏指导类固醇使用剂量和持续时间以及处理难治性疾病的治疗建议。本综述揭示了治疗 IBD 肺部并发症的不同策略,包括使用免疫调节疗法的新型治疗方法,并总结了这些并发症的临床和影像学特征以及病理学相关性。
{"title":"Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies","authors":"Subha Ghosh MD, MBA ,&nbsp;Himanshu Deshwal MD ,&nbsp;Rebecca Haraf MD ,&nbsp;Shine Raju MD ,&nbsp;Mnahi Bin Saeedan MBBS, MPH ,&nbsp;Pralay Sarkar MD, FCCP ,&nbsp;Thomas Gildea MD ,&nbsp;Carol F. Farver MD ,&nbsp;Atul C. Mehta MD, FCCP","doi":"10.1016/j.chpulm.2023.100018","DOIUrl":"10.1016/j.chpulm.2023.100018","url":null,"abstract":"<div><h3>Topic Importance</h3><p>Ulcerative colitis and Crohn’s disease are multisystem illnesses that primarily affect the gut, but present with various extraintestinal manifestations. The pathogenesis behind these clinical features is poorly understood, and pulmonary manifestations of inflammatory bowel disease (IBD) are no exception. Research has suggested an intricate interplay between the mucosal immune system and the microbiotic environment between the gut and the lung, often termed the <em>gut-lung axis</em>. This dysregulated communication is demonstrated in a wide range of pulmonary complications involving the large and small airways, lung parenchyma, serosal tissues, and pulmonary vasculature; fistulous connection between the gastrointestinal tract and thoracic cavity; and drug toxicities. Most of these diseases have been well documented in case reports to respond to corticosteroid treatment regimens. However, a notable lack of treatment recommendations guiding the dosage and duration of steroid use and managing the disease refractory to therapy are available. In addition, the progressive and debilitating disease often remains a therapeutic challenge.</p></div><div><h3>Review Findings</h3><p>This review sheds light on the different strategies documented to treat the spectrum of pulmonary complications of IBD, including novel therapeutic approaches using immunomodulatory therapy, and summarizes their clinical and radiologic features with pathologic correlation.</p></div><div><h3>Summary</h3><p>Although their existence is well documented, further research is needed to develop evidence-based guidelines for diagnosing, managing, and preventing pulmonary complications of IBD.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 3","pages":"Article 100018"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000181/pdfft?md5=08e6072816e229b0f88a7156fcc4b9e9&pid=1-s2.0-S2949789223000181-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135248531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acquisition of Cardiac Point-of-Care Ultrasound Images With Deep Learning 心脏护理点超声图像的深度学习获取
Pub Date : 2023-12-01 DOI: 10.1016/j.chpulm.2023.100023
Evan Baum MD , Megha D. Tandel MPH , Casey Ren MD , Yingjie Weng MS , Matthew Pascucci MD , John Kugler MD , Kathryn Cardoza MD , Andre Kumar MD, MEd

Background

Point-of-care ultrasonography (POCUS) machines may use deep learning, a subfield of artificial intelligence (AI), to improve image interpretation and acquisition in real time. The impact of AI on POCUS learning is unknown.

Research Question

Do AI-enhanced devices equipped with deep learning aid in cardiac image acquisition and interpretation among POCUS novices?

Study Design and Methods

We conducted a single-center investigation from 2021 through 2022. Internal medicine trainees (N = 43) with limited POCUS experience were randomized to receive a POCUS device with (Echonous; n = 22) or without (Butterfly; n = 21) AI functionality for 2 weeks while on inpatient rotations. AI device functionality included guidance for optimal probe placement to acquire an apical four-chamber (A4C) view and ejection fraction estimations based on deep learning. Participants used the devices at their discretion for patient-related care after randomization. The primary outcome was the time to acquire A4C images on a standardized patient. Secondary outcomes included A4C image quality using a validated scale, image quiz performance, and attitudes. Measurements were performed at randomization and at 2-week follow-up using the same standardized patient.

Results

Both AI and non-AI groups showed similar scan times and image quality scores at baseline. At follow-up, the AI group showed faster scan times (57 s [interquartile range (IQR), 32-75 s] vs 85 s [IQR, 50-172 s]; P = .01), higher image quality scores (4.5 [IQR, 2-5.5] vs 2 [IQR, 1-3]; P < .01), and more accurately identified reduced systolic function on the image quiz (85% vs 50%; P = .02) vs the non-AI group. The AI group used the devices more than the non-AI group (median, 5.5 times [IQR, 4-10 times] vs 2 times [IQR, 0-4 times]; P < .01). Trust in the AI features did not change during the intervention.

Interpretation

POCUS devices with deep learning functionality may improve A4C image acquisition and interpretation by novices. Future studies are needed to determine the extent that AI impacts POCUS learning.

护理点超声检查(POCUS)机器可以使用人工智能(AI)的一子领域——深度学习来改进实时图像解释和采集。人工智能对POCUS学习的影响尚不清楚。配备深度学习的人工智能增强设备是否有助于POCUS新手的心脏图像采集和解释?研究设计和方法我们从2021年到2022年进行了一项单中心调查。具有有限POCUS经验的内科实习生(N = 43)随机接受POCUS装置(Echonous;n = 22)或不含(Butterfly;n = 21)在住院病人轮转期间使用人工智能功能2周。人工智能设备功能包括指导最佳探针放置,以获得顶点四室(A4C)视图和基于深度学习的射血分数估计。随机分组后,参与者自行决定使用这些设备进行与患者相关的护理。主要结果是获得标准化患者A4C图像的时间。次要结果包括使用有效量表的A4C图像质量,图像测验表现和态度。在随机化和2周的随访中对同一标准化患者进行测量。结果人工智能组和非人工智能组在基线时的扫描时间和图像质量得分相似。在随访中,人工智能组的扫描时间更快(57 s[四分位间距,32-75 s] vs 85 s[四分位间距,50-172 s]);P = 0.01),更高的图像质量评分(4.5 [IQR, 2-5.5] vs 2 [IQR, 1-3];P & lt;.01),在图像测试中更准确地识别出收缩功能下降(85% vs 50%;P = .02)与非ai组相比。人工智能组使用设备的次数多于非人工智能组(中位数,5.5次[IQR, 4-10次]vs 2次[IQR, 0-4次];P & lt;. 01)。在干预期间,对人工智能功能的信任没有改变。具有深度学习功能的pocus设备可以改善新手的A4C图像采集和解释。未来的研究需要确定人工智能对POCUS学习的影响程度。
{"title":"Acquisition of Cardiac Point-of-Care Ultrasound Images With Deep Learning","authors":"Evan Baum MD ,&nbsp;Megha D. Tandel MPH ,&nbsp;Casey Ren MD ,&nbsp;Yingjie Weng MS ,&nbsp;Matthew Pascucci MD ,&nbsp;John Kugler MD ,&nbsp;Kathryn Cardoza MD ,&nbsp;Andre Kumar MD, MEd","doi":"10.1016/j.chpulm.2023.100023","DOIUrl":"10.1016/j.chpulm.2023.100023","url":null,"abstract":"<div><h3>Background</h3><p>Point-of-care ultrasonography (POCUS) machines may use deep learning, a subfield of artificial intelligence (AI), to improve image interpretation and acquisition in real time. The impact of AI on POCUS learning is unknown.</p></div><div><h3>Research Question</h3><p>Do AI-enhanced devices equipped with deep learning aid in cardiac image acquisition and interpretation among POCUS novices?</p></div><div><h3>Study Design and Methods</h3><p>We conducted a single-center investigation from 2021 through 2022. Internal medicine trainees (N = 43) with limited POCUS experience were randomized to receive a POCUS device with (Echonous; n = 22) or without (Butterfly; n = 21) AI functionality for 2 weeks while on inpatient rotations. AI device functionality included guidance for optimal probe placement to acquire an apical four-chamber (A4C) view and ejection fraction estimations based on deep learning. Participants used the devices at their discretion for patient-related care after randomization. The primary outcome was the time to acquire A4C images on a standardized patient. Secondary outcomes included A4C image quality using a validated scale, image quiz performance, and attitudes. Measurements were performed at randomization and at 2-week follow-up using the same standardized patient.</p></div><div><h3>Results</h3><p>Both AI and non-AI groups showed similar scan times and image quality scores at baseline. At follow-up, the AI group showed faster scan times (57 s [interquartile range (IQR), 32-75 s] vs 85 s [IQR, 50-172 s]; <em>P</em> = .01), higher image quality scores (4.5 [IQR, 2-5.5] vs 2 [IQR, 1-3]; <em>P</em> &lt; .01), and more accurately identified reduced systolic function on the image quiz (85% vs 50%; <em>P</em> = .02) vs the non-AI group. The AI group used the devices more than the non-AI group (median, 5.5 times [IQR, 4-10 times] vs 2 times [IQR, 0-4 times]; <em>P</em> &lt; .01). Trust in the AI features did not change during the intervention.</p></div><div><h3>Interpretation</h3><p>POCUS devices with deep learning functionality may improve A4C image acquisition and interpretation by novices. Future studies are needed to determine the extent that AI impacts POCUS learning.</p></div>","PeriodicalId":94286,"journal":{"name":"CHEST pulmonary","volume":"1 3","pages":"Article 100023"},"PeriodicalIF":0.0,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949789223000235/pdfft?md5=f2f40d80c3cfa78dc9225371899bac67&pid=1-s2.0-S2949789223000235-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135434384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
期刊
CHEST pulmonary
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1